Marin County's Ultragenyx Pharmaceutical estimates sales grew nearly 20% in 2023
Ultragenyx's Corporate Sustainability Journey—Ultragenyx
Ultragenyx Enters into Strategic Partnership with Daiichi Sankyo for Gene Therapy Manufacturing Technology | World Pharma Today
Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New Gene Therapies for Duchenne Muscular Dystrophy - Jett Foundation
Ultragenyx Fights for Cures Amid Rising R&D Costs - NAM
Events & presentations—Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Development Pipeline – Angelman Syndrome Foundation
Ultragenyx Receives an Extended Approval for Evkeeza by the EC for 5 Years or Older Children with Homozygous Familial Hypercholesterolemia (HoFH)
Press releases—Ultragenyx Pharmaceutical Inc.
Press releases—Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Q4 2022 Earnings Transcript
Ultragenyx Overview | SignalHire Company Profile
Events & presentations—Ultragenyx Pharmaceutical Inc.
Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New Gene Therapies for Duchenne Muscular Dystrophy - CureDuchenne
Ultragenyx Pharmaceutical Inc. (RARE) Stock Price, Quote & News - Stock Analysis
Ultragenyx Issues 2022 ESG Report, Continuing To Enhance Its Leadership on Corporate Responsibility
Ultragenyx: Outstanding Q4 2018 Results (NASDAQ:RARE) | Seeking Alpha
Ultragenyx Pharmaceutical, Inc. Aktie News
Press releases—Ultragenyx Pharmaceutical Inc.
Marin County's Ultragenyx Pharmaceutical reports Q2 loss of nearly $160 million
Investors & Media—Ultragenyx Pharmaceutical Inc.
Press releases—Ultragenyx Pharmaceutical Inc.
FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS (FAST) ANNOUNCES SALE OF ITS SHARES IN GENETX TO ULTRAGENYX
Ultragenyx Announces Proposed Public Offering of Common Stock | RARE Stock News
